Erik J. Bidstrup
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Erik J. Bidstrup has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Michael C. Jewett
Northwestern University
5 shared publications - Matthew P. DeLisa
Robert F. Smith School of Chemical and Biomolecular Engineering, Cornell University
4 shared publications - Lai-Xi Wang
Department of Chemistry and Biochemistry, University of Maryland, College Park, MD 20742, USA
3 shared publications Alexandra Pang
Robert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, USA
2 shared publications- Belen Sotomayor
Robert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, USA
2 shared publications - Christopher A. Alabi
Robert F. Smith School of Chemical and Biomolecular Engineering, Cornell University
2 shared publications
Latest Publications
- Open Access
- 4 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-16
Discovery of a single-subunit oligosaccharyltransferase that enables glycosylation of full-length IgG antibodies in bacteria
Human immunoglobulin G (IgG) antibodies are a major class of biotherapeutics and undergo N-linked glycosylation in their Fc domain, which is critical for immune functions and therapeutic activity. Hence, technologies for producing authentically glycosylated IgGs are in high demand. Previous attempts to engineer Escherichia coli for this purpose have met limited success due in part to the lack of oligosaccharyltransferase (OST) enzymes that can install N-glycans at the conserved N297 site in the Fc region. Here, we identify a single-subunit OST from Desulfovibrio marinus with relaxed substrate specificity that catalyzes glycosylation of native Fc acceptor sites. By chemoenzymatic remodeling the attached bacterial glycans to homogeneous, asialo complex-type G2 N-glycans, the E. coli-derived Fc binds human FcγRIIIa/CD16a, a key receptor for antibody-dependent cellular cytotoxicity (ADCC). Overall, the discovery of D. marinus OST provides previously unavailable biocatalytic capabilities and sets the stage for using E. coli to produce fully human antibodies.
- 4 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-16
Open AccessDiscovery of a single-subunit oligosaccharyltransferase that enables glycosylation of full-length IgG antibodies in bacteria
Human immunoglobulin G (IgG) antibodies are a major class of biotherapeutics and undergo N-linked glycosylation in their Fc domain, which is critical for immune functions and therapeutic activity. Hence, technologies for producing authentically glycosylated IgGs are in high demand. Previous attempts to engineer Escherichia coli for this purpose have met limited success due in part to the lack of oligosaccharyltransferase (OST) enzymes that can install N-glycans at the conserved N297 site in the Fc region. Here, we identify a single-subunit OST from Desulfovibrio marinus with relaxed substrate specificity that catalyzes glycosylation of native Fc acceptor sites. By chemoenzymatic remodeling the attached bacterial glycans to homogeneous, asialo complex-type G2 N-glycans, the E. coli-derived Fc binds human FcγRIIIa/CD16a, a key receptor for antibody-dependent cellular cytotoxicity (ADCC). Overall, the discovery of D. marinus OST provides previously unavailable biocatalytic capabilities and sets the stage for using E. coli to produce fully human antibodies.
- 28 May 2025
- Published by American Chemical Society (ACS) in ACS Synthetic Biology
- Vol. 14 (6) , 2354-2367
Glycosylation of Structured Protein Domains in Cell-Free Reaction Environments
The production of N-linked glycoproteins in genetically tractable bacterial hosts and their cell-free extracts holds great promise for low-cost, customizable, and distributed biomanufacturing of glycoconjugate vaccines and glycoprotein therapeutics. In nearly all bacterial N-linked protein glycosylation systems described so far, a single-subunit, transmembrane oligosaccharyltransferase (OST) is employed which favors acceptor sites in flexible, solvent-exposed motifs of the glycoprotein substrate. Yet despite this preference, acceptor sites in structured domains can also be glycosylated in living bacteria, presumably by a mechanism where the site is presented to the OST in a flexible form during or after the membrane translocation step but prior to folding being completed. While N-glycoprotein biosynthesis can also be accomplished using cell-free extracts derived from glycosylation-competent bacteria, it remains to be determined whether the cell-free reaction environment involves a similar mechanism for glycosylation of structured domains. Using anEscherichia coli-based cell-free glycoprotein synthesis (CFGpS) system, we observed efficient glycosylation of two eukaryotic glycoproteins, namely ribonuclease A (RNase A) and the fragment crystallizable (Fc) region of human immunoglobulin G (IgG), whose acceptor sites occur in structurally constrained regions that were not glycosylated when the proteins were already folded. Because this cell-free glycosylation depended on ribosomal translation but not on signal peptide-mediated translocation, we propose the existence of a unique cotranslational, but not cotranslocational, glycosylation mechanism in CFGpS. Collectively, these findings reveal the potential for CFGpS to become a viable platform for producing complex eukaryotic glycoprotein targets.
- 28 May 2025
- Published by American Chemical Society (ACS) in ACS Synthetic Biology
- Vol. 14 (6) , 2354-2367
Glycosylation of Structured Protein Domains in Cell-Free Reaction Environments
The production of N-linked glycoproteins in genetically tractable bacterial hosts and their cell-free extracts holds great promise for low-cost, customizable, and distributed biomanufacturing of glycoconjugate vaccines and glycoprotein therapeutics. In nearly all bacterial N-linked protein glycosylation systems described so far, a single-subunit, transmembrane oligosaccharyltransferase (OST) is employed which favors acceptor sites in flexible, solvent-exposed motifs of the glycoprotein substrate. Yet despite this preference, acceptor sites in structured domains can also be glycosylated in living bacteria, presumably by a mechanism where the site is presented to the OST in a flexible form during or after the membrane translocation step but prior to folding being completed. While N-glycoprotein biosynthesis can also be accomplished using cell-free extracts derived from glycosylation-competent bacteria, it remains to be determined whether the cell-free reaction environment involves a similar mechanism for glycosylation of structured domains. Using anEscherichia coli-based cell-free glycoprotein synthesis (CFGpS) system, we observed efficient glycosylation of two eukaryotic glycoproteins, namely ribonuclease A (RNase A) and the fragment crystallizable (Fc) region of human immunoglobulin G (IgG), whose acceptor sites occur in structurally constrained regions that were not glycosylated when the proteins were already folded. Because this cell-free glycosylation depended on ribosomal translation but not on signal peptide-mediated translocation, we propose the existence of a unique cotranslational, but not cotranslocational, glycosylation mechanism in CFGpS. Collectively, these findings reveal the potential for CFGpS to become a viable platform for producing complex eukaryotic glycoprotein targets.
- Open Access
Discovery of a single-subunit oligosaccharyltransferase that enables glycosylation of full-length IgG antibodies in Escherichia coli
Human immunoglobulin G (IgG) antibodies are one of the most important classes of biotherapeutic agents and undergo glycosylation at the conserved N297 site in the C H 2 domain, which is critical for IgG Fc effector functions and anti-inflammatory activity. Hence, technologies for producing authentically glycosylated IgGs are in high demand. While attempts to engineer Escherichia coli for this purpose have been described, they have met limited success due in part to the lack of available oligosaccharyltransferase (OST) enzymes that can install N- linked glycans within the QYNST sequon of the IgG C H 2 domain. Here, we identified a previously uncharacterized single-subunit OST (ssOST) from the bacterium Desulfovibrio marinus that exhibited greatly relaxed substrate specificity and, as a result, was able to catalyze glycosylation of native C H 2 domains in the context of both a hinge-Fc fragment and a full-length IgG. Although the attached glycans were bacterial in origin, conversion to a homogeneous, asialo complex-type G2 N -glycan at the QYNST sequon of the E. coli -derived hinge-Fc was achieved via chemoenzymatic glycan remodeling. Importantly, the resulting G2-hinge-Fc exhibited strong binding to human FcγRIIIa (CD16a), one of the most potent receptors for eliciting antibody-dependent cellular cytotoxicity (ADCC). Taken together, the discovery of a unique ssOST from D. marinus provides previously unavailable biocatalytic capabilities to the bacterial glycoprotein engineering toolbox and opens the door to using E. coli for the production and glycoengineering of human IgGs and fragments derived thereof.
Open AccessDiscovery of a single-subunit oligosaccharyltransferase that enables glycosylation of full-length IgG antibodies in Escherichia coli
Human immunoglobulin G (IgG) antibodies are one of the most important classes of biotherapeutic agents and undergo glycosylation at the conserved N297 site in the C H 2 domain, which is critical for IgG Fc effector functions and anti-inflammatory activity. Hence, technologies for producing authentically glycosylated IgGs are in high demand. While attempts to engineer Escherichia coli for this purpose have been described, they have met limited success due in part to the lack of available oligosaccharyltransferase (OST) enzymes that can install N- linked glycans within the QYNST sequon of the IgG C H 2 domain. Here, we identified a previously uncharacterized single-subunit OST (ssOST) from the bacterium Desulfovibrio marinus that exhibited greatly relaxed substrate specificity and, as a result, was able to catalyze glycosylation of native C H 2 domains in the context of both a hinge-Fc fragment and a full-length IgG. Although the attached glycans were bacterial in origin, conversion to a homogeneous, asialo complex-type G2 N -glycan at the QYNST sequon of the E. coli -derived hinge-Fc was achieved via chemoenzymatic glycan remodeling. Importantly, the resulting G2-hinge-Fc exhibited strong binding to human FcγRIIIa (CD16a), one of the most potent receptors for eliciting antibody-dependent cellular cytotoxicity (ADCC). Taken together, the discovery of a unique ssOST from D. marinus provides previously unavailable biocatalytic capabilities to the bacterial glycoprotein engineering toolbox and opens the door to using E. coli for the production and glycoengineering of human IgGs and fragments derived thereof.
- Open Access
- 18 November 2022
- Published by American Chemical Society (ACS) in ACS Synthetic Biology
- Vol. 11 (12) , 3892-3899
Ribosome Stalling of N-Linked Glycoproteins in Cell-Free Extracts
Ribosome display is a powerful in vitro method for selection and directed evolution of proteins expressed from combinatorial libraries. However, the ability to display proteins with complex post-translational modifications such as glycosylation is limited. To address this gap, we developed a set of complementary methods for producing stalled ribosome complexes that displayed asparagine-linked (N-linked) glycoproteins in conformations amenable to downstream functional and glycostructural interrogation. The ability to generate glycosylated ribosome-nascent chain (glycoRNC) complexes was enabled by integrating SecM-mediated translation arrest with methods for cell-free N-glycoprotein synthesis. This integration enabled a first-in-kind method for ribosome stalling of target proteins modified efficiently and site-specifically with different N-glycan structures. Moreover, the observation that encoding mRNAs remained stably attached to ribosomes provides evidence of a genotype-glycophenotype link between an arrested glycoprotein and its RNA message. We anticipate that our method will enable selection and evolution of N-glycoproteins with advantageous biological and biophysical properties.
- 18 November 2022
- Published by American Chemical Society (ACS) in ACS Synthetic Biology
- Vol. 11 (12) , 3892-3899
Open AccessRibosome Stalling of N-Linked Glycoproteins in Cell-Free Extracts
Ribosome display is a powerful in vitro method for selection and directed evolution of proteins expressed from combinatorial libraries. However, the ability to display proteins with complex post-translational modifications such as glycosylation is limited. To address this gap, we developed a set of complementary methods for producing stalled ribosome complexes that displayed asparagine-linked (N-linked) glycoproteins in conformations amenable to downstream functional and glycostructural interrogation. The ability to generate glycosylated ribosome-nascent chain (glycoRNC) complexes was enabled by integrating SecM-mediated translation arrest with methods for cell-free N-glycoprotein synthesis. This integration enabled a first-in-kind method for ribosome stalling of target proteins modified efficiently and site-specifically with different N-glycan structures. Moreover, the observation that encoding mRNAs remained stably attached to ribosomes provides evidence of a genotype-glycophenotype link between an arrested glycoprotein and its RNA message. We anticipate that our method will enable selection and evolution of N-glycoproteins with advantageous biological and biophysical properties.
- 14 July 2022
- Published by Springer Nature in Nature Chemical Biology
- Vol. 18 (9) , 990-998
Three-dimensional structure-guided evolution of a ribosome with tethered subunits
RNA-based macromolecular machines, such as the ribosome, have functional parts reliant on structural interactions spanning sequence-distant regions. These features limit evolutionary exploration of mutant libraries and confound three-dimensional structure-guided design. To address these challenges, we describe Evolink (evolution and linkage), a method that enables high-throughput evolution of sequence-distant regions in large macromolecular machines, and library design guided by computational RNA modeling to enable exploration of structurally stable designs. Using Evolink, we evolved a tethered ribosome with a 58% increased activity in orthogonal protein translation and a 97% improvement in doubling times in SQ171 cells compared to a previously developed tethered ribosome, and reveal new permissible sequences in a pair of ribosomal helices with previously explored biological function. The Evolink approach may enable enhanced engineering of macromolecular machines for new and improved functions for synthetic biology.
- 14 July 2022
- Published by Springer Nature in Nature Chemical Biology
- Vol. 18 (9) , 990-998
Three-dimensional structure-guided evolution of a ribosome with tethered subunits
RNA-based macromolecular machines, such as the ribosome, have functional parts reliant on structural interactions spanning sequence-distant regions. These features limit evolutionary exploration of mutant libraries and confound three-dimensional structure-guided design. To address these challenges, we describe Evolink (evolution and linkage), a method that enables high-throughput evolution of sequence-distant regions in large macromolecular machines, and library design guided by computational RNA modeling to enable exploration of structurally stable designs. Using Evolink, we evolved a tethered ribosome with a 58% increased activity in orthogonal protein translation and a 97% improvement in doubling times in SQ171 cells compared to a previously developed tethered ribosome, and reveal new permissible sequences in a pair of ribosomal helices with previously explored biological function. The Evolink approach may enable enhanced engineering of macromolecular machines for new and improved functions for synthetic biology.